Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VALE: Long-term Extension Study of Pegcetacoplan in C3G or IC-MPGN
NCT05809531Phase 3Active, not recruiting
- Sponsor
- Apellis Pharmaceuticals
- Start
- May 2023
- Primary completion
- Jul 2027
- Modality
- PEGylated Peptides
- Countries
- 15
01
Overview
A Phase 3 trial of pegcetacoplan in Complement 3 glomerulopathy (C3G), Immune Complex Membranoproliferative Glomerulonephritis (IC-MPGN), sponsored by Apellis Pharmaceuticals. Started May 2023; status: active, not recruiting.
02
Drugs
pegcetacoplan
03
Conditions
Complement 3 glomerulopathy (C3G)Immune Complex Membranoproliferative Glomerulonephritis (IC-MPGN)
Beyond the preview
Go deeper on NCT05809531.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05809531.